非小细胞肺癌组织中程序性死亡蛋白1及其配体表达的临床意义与检测方法

The clinical significance and detection methods of programmed death protein 1 and its ligand expression in non-small cell lung cancer

近年来,程序性死亡蛋白1及其配体(PD-1/PD-L1)通路作为肿瘤治疗的主要研究方向,为部分非小细胞肺癌患者的治疗方式带来了变革。抗PD-L1抑制剂的疗效与肿瘤组织中PD-L1的表达呈正相关。但是,现阶段各种PD-1/PD-L1抑制剂均有不同的PD-L1表达检测技术。因此,如何高效、准确的检测肿瘤组织中PD-L1的表达显得尤为重要。本研究针对非小细胞肺癌组织中PD-L1表达的临床意义、检测方法的研究进展进行综述。

In recent years,programmed death protein 1 and its ligand(PD-1/PD-L1)pathway as the main research direction of tumor therapy has brought changes to the treatment of non-small cell lung cancer in some patients.The curative effects of anti-PD-L1 inhibitors are positively correlated with the expression of PD-L1 in tumor tissues.However,different techniques are required to detect the expression of PD-L1 after application of different PD-1/PD-L1 inhibitors.Therefore,how to detect the expression of PD-L1 in tumor tissues efficiently and accurately is particularly important.This review summarizes the clinical significance and detection methods of PD-L1 expression in non-small cell lung cancer.